Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health
Milestone financing and R&D collaboration advances gene therapy programs targeting chronic and age-related diseases in companion animals. Norwalk, CT – June 11, 2026 – Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congratulates its portfolio company Rejuvenate Bio on the successful close of a $6 million financing round and the announcement of a strategic research and development collaboration with Merck Animal Health
Lifespan Vision Ventures Leads Violet Therapeutics’ $4.75M Seed Extension Financing
Norwalk, CT - May 13, 2026 - Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, today announced that it has led Violet Therapeutics’ $4.75 million seed extension financing, with participation from Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures. Violet Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapies for neurodegenerative disease by mapp
Lifespan Vision Ventures Co-Leads Sift Biosciences’ $3.7M Pre-Seed Financing
Norwalk, CT – February 18, 2026 – Lifespan Vision Ventures, an investment firm focused on therapeutics that improve human healthspan, today announced that it has co-led Sift Biosciences’ oversubscribed $3.7 million Pre-Seed financing alongside Freeflow Ventures, with participation from Valuence Ventures, Eisai Innovation, SBI US Gateway Fund, and other early investors. Sift Biosciences is developing a peptide-based immunotherapy platform designed to harness pre-existing immun
Lifespan Vision Ventures Invests in TECregen’s Seed Financing
Norwalk, CT – January 8, 2026 - Lifespan Vision Ventures, an investment firm focused on therapeutics that improve human healthspan, today announced an investment in TECregen’s CHF 10 million seed financing round. Lifespan Vision Ventures joins lead investor Boehringer Ingelheim Venture Fund (BIVF), along with Carma Fund, EOS BioInnovation, High-Tech Gründerfonds (HTGF), the JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank. TECregen is developi